These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15295222)

  • 1. Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine.
    Talbot TR; Poehling KA; Hartert TV; Arbogast PG; Halasa NB; Mitchel E; Schaffner W; Craig AS; Edwards KM; Griffin MR
    Pediatr Infect Dis J; 2004 Aug; 23(8):726-31. PubMed ID: 15295222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine.
    Talbot TR; Poehling KA; Hartert TV; Arbogast PG; Halasa NB; Mitchel E; Schaffner W; Craig AS; Edwards KM; Griffin MR
    Clin Infect Dis; 2004 Sep; 39(5):641-8. PubMed ID: 15356776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.
    Hsu K; Pelton S; Karumuri S; Heisey-Grove D; Klein J;
    Pediatr Infect Dis J; 2005 Jan; 24(1):17-23. PubMed ID: 15665705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
    Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.
    Halasa NB; Shankar SM; Talbot TR; Arbogast PG; Mitchel EF; Wang WC; Schaffner W; Craig AS; Griffin MR
    Clin Infect Dis; 2007 Jun; 44(11):1428-33. PubMed ID: 17479937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections.
    Flannery B; Schrag S; Bennett NM; Lynfield R; Harrison LH; Reingold A; Cieslak PR; Hadler J; Farley MM; Facklam RR; Zell ER; Whitney CG;
    JAMA; 2004 May; 291(18):2197-203. PubMed ID: 15138241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Socioeconomic and racial disparities of pediatric invasive pneumococcal disease after the introduction of the 7-valent pneumococcal conjugate vaccine.
    Spicer JO; Thomas S; Holst A; Baughman W; Farley MM
    Pediatr Infect Dis J; 2014 Feb; 33(2):158-64. PubMed ID: 24418837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial and Regional Differences in Rates of Invasive Pneumococcal Disease.
    de St Maurice A; Grijalva CG; Fonnesbeck C; Schaffner W; Halasa NB
    Pediatrics; 2015 Nov; 136(5):e1186-94. PubMed ID: 26459652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial disparities in invasive Streptococcus pneumoniae infections, 1998-2009.
    Wortham JM; Zell ER; Pondo T; Harrison LH; Schaffner W; Lynfield R; Thomas A; Reingold A; Bennett NM; Petit S; Aragon D; Bareta J; Juni BA; Farley MM; Beall B; Moore MR
    Clin Infect Dis; 2014 May; 58(9):1250-7. PubMed ID: 24585565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
    Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity.
    Hennessy TW; Singleton RJ; Bulkow LR; Bruden DL; Hurlburt DA; Parks D; Moore M; Parkinson AJ; Schuchat A; Butler JC
    Vaccine; 2005 Dec; 23(48-49):5464-73. PubMed ID: 16188350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV).
    Meiring S; Cohen C; Quan V; de Gouveia L; Feldman C; Karstaedt A; Klugman KP; Madhi SA; Rabie H; Sriruttan C; von Gottberg A;
    PLoS One; 2016; 11(2):e0149104. PubMed ID: 26863135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent Sex Disparities in Invasive Pneumococcal Diseases in the Conjugate Vaccine Era.
    de St Maurice A; Schaffner W; Griffin MR; Halasa N; Grijalva CG
    J Infect Dis; 2016 Sep; 214(5):792-7. PubMed ID: 27247342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance among isolates causing invasive pneumococcal disease before and after licensure of heptavalent conjugate pneumococcal vaccine.
    Karnezis TT; Smith A; Whittier S; Haddad J; Saiman L
    PLoS One; 2009 Jun; 4(6):e5965. PubMed ID: 19536335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.
    Tomczyk S; Lynfield R; Schaffner W; Reingold A; Miller L; Petit S; Holtzman C; Zansky SM; Thomas A; Baumbach J; Harrison LH; Farley MM; Beall B; McGee L; Gierke R; Pondo T; Kim L
    Clin Infect Dis; 2016 May; 62(9):1119-25. PubMed ID: 26908787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002--implications for vaccine serotype coverage.
    Watson M; Bayley K; Bell JM; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Roche P; Smith HV; Stewart MG; Stylianopoulos J; Turnidge J
    Commun Dis Intell Q Rep; 2003; 27(4):478-87. PubMed ID: 15508501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
    Izurieta P; Bahety P; Adegbola R; Clarke C; Hoet B
    Expert Rev Vaccines; 2018 Jun; 17(6):479-493. PubMed ID: 29241390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.